Five Point Holdings LLC and City of Hope said today they plan to build a $200 million cancer center at the Great Park Neighborhoods in Irvine.
Fujifilm Holdings plans to buy a pair of cell culture media businesses owned by Japanese oil and metals conglomerate JXTG Holdings for about $800 million.
Justice Department lawyers said this week they plan to try medical-device executive Jim Mazzo for a third time for violating insider trading rules after two prior efforts ended in hung juries.
Providence St. Joseph named Victor Jordan chief operating officer for Providence St. Joseph Health Southern California, effective March 26.
Hoag Memorial Hospital Presbyterian in Newport Beach has assumed the title sponsorship of Orange County’s only PGA Tour event, renaming it the Hoag Classic.
Seattle-based SightLife Surgical Inc. will buy the Kamra inlay from AcuFocus Inc. in Irvine on undisclosed terms in a deal expected to close this month.
Long Beach Medical Center filed a 120-day lease termination notice on behalf of Community Medical Center Long Beach.
Biologics manufacturer Avid Bioservices Inc. announced Chief Financial Officer Paul Lytle resigned, effective May 24.
Nemus Bioscience Inc. (OTCQB: NMUS) received a $1.75 million private placement from majority shareholder Emerald Health Sciences Inc. and other investors.
Tustin-based Avid Bioservices Inc. yesterday priced a public offering of 9 million shares of common stock at $2.25 apiece, and expects more than $20 million in gross proceeds after the offering closes next week.
For the second time in a year, the fate of Jim Mazzo is in the hands of a federal jury. Prosecutors are again alleging that the founder and former chief executive of Advanced Medical Optics (AMO) violated insider trading laws when he disclosed to his friend and Laguna Beach neighbor Doug DeCinces that his company was being bought by Abbott Laboratories.
Avid Bioservices Inc. in Tustin will sell its clinical-stage immunotherapy cancer drug candidate to Oncologie Inc. for $8 million upfront—with payments spread over six months—and up to $95 million in development, regulatory and commercialization milestones.
Lake Forest-based ReVision Optics Inc. has shut down saying, “it is with regret, that we have to close our doors.”
Irvine-based Evolus Inc. priced its initial public offering of five million shares of common stock at $12 per share, the low end of an earlier-announced $12 to $14 range.